

ALZHEIMER'S DISEASE

- Afflicts more than 5 million individuals in the United States.
- Anticipated to increase to approximately 15 million by 2050.

AGITATION IN ALZHEIMER'S DISEASE

- Up to 70% of patients experience symptoms of agitation or aggression (emotional distress, aggressive or disruptive behaviors, shouting and disinhibition).
- Agitation symptoms increase caregiver burden, decrease patient functioning, can result in earlier nursing home placement and increased mortality risk.

AGITATION IN ALZHEIMER'S DISEASE REMAINS A CHALLENGE WITH NO APPROVED THERAPIES.


THE ACCORD STUDY IS INVESTIGATING A POTENTIAL TREATMENT.

#32294564.0 IRB Approved at the Protocol Level Oct. 14, 2021

AXS-05

AXS-05 is a novel fixed-dose combination of bupropion and dextromethorphan.

Inhibits DM metabolism



Pharmacodynamic Synergy

MECHANISM OF ACTION	DM	BUP	AXS-05 (DM+BUP)
NMDA Receptor Antagonist	✓		√
Sigma-1 Receptor Agonist	✓		✓
Norepinephrine Reuptake Inhibitor	✓	✓	✓
Serotonin Reuptake Inhibitor	✓		✓
Dopamine Reuptake Inhibitor		✓	√
Nicotinic ACh Receptor Antagonist		✓	√



For more information visit ACCORD-study.com
ClinicalTrials.Gov Identifier: NCT04797715

AVSOME and its long are registered trademarks of Avsome Theorems Linear Control of the Control of

AXSOME and its logo are registered trademarks of Axsome Therapeutics, Inc. © 2021 Axsome Therapeutics, Inc. All rights reserved. 03/2021



A Double-blind, Placebo-controlled Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects with Dementia of the Alzheimer's Type

STUDY DESIGN

clinical response

Treatment Period: Up to 35 weeks



KEY ELIGIBILITY CRITERIA*

- 65-90 years of age, inclusive
- · A probable diagnosis of Alzheimer's disease
- Symptoms of agitation or aggression resulting in distress in their home
- A supportive, consistent, and reliable caregiver willing to participate
- *Other criteria apply.